A growing trend observed in pediatric sleep clinics nationwide reveals a consistent pattern: a significant number of children presenting with sleep disturbances have either used melatonin or are currently taking it. Melatonin, a hormone naturally produced by the body, is widely recognized as a valuable tool in managing various sleep disorders in pediatric populations. Its natural origin has fostered a pervasive perception of its inherent safety, leading to its increasingly frequent and, in some cases, unsupervised administration. This widespread reliance has prompted concern among medical professionals regarding the long-term implications and appropriate usage of this supplement.
The exact prevalence of melatonin use in children remains difficult to quantify precisely. However, data from broader studies offer insights into its escalating consumption. A notable study published in JAMA in 2022 estimated that melatonin use among adults had tripled between 2005 and 2018, with a concurrent increase in dosage levels. This trend is mirrored, and potentially amplified, in the pediatric market, where melatonin products are being aggressively marketed to parents. This aggressive marketing, coupled with the supplement’s over-the-counter availability, has led to a concerning scenario where some parents may be resorting to melatonin as a convenient shortcut, potentially bypassing the implementation of crucial, foundational sleep hygiene practices. Anecdotal evidence, such as a father’s review on Amazon quoted in a Wall Street Journal article, illustrates this sentiment: "OK, yes, as parents my wife and I should do a better job starting the bedtime routine earlier, turning off the TV earlier, limiting sweets, etc., etc. Well, for whatever reason, this is not our strong suit. This 1 mg light dosage of melatonin is very helpful winding our kids down and getting them ready for bed." This sentiment highlights a common parental dilemma, where time constraints and the desire for a quick solution can override the sustained effort required for establishing healthy sleep habits.
Escalating Consumption and Global Trends
The surge in melatonin usage among children is a global phenomenon, with various studies and reports indicating a dramatic increase in prescriptions and over-the-counter sales. A New York Times article from May 2020, titled "Parents Are Relying on Melatonin to Help Their Kids Sleep. Should They?", highlighted an 87% increase in overall melatonin sales in the year preceding March 2020. A survey conducted by the Times revealed that out of 933 parents with children under 18, one-third reported their child having experienced sleep difficulties in the past year, and over half had administered melatonin to their children at some point.
More recent data underscores the escalating nature of this trend. In Scandinavia, there has been an almost 500% increase in melatonin prescriptions. In the United States, melatonin has become the most common cause of accidental overdose in pediatric emergency rooms and a leading reason for calls to poison control centers. This pattern suggests a widespread and growing reliance on melatonin as a sleep aid for children, prompting a closer examination of its efficacy, safety, and appropriate application.
Understanding Melatonin: Function and Misconceptions
Melatonin is a hormone naturally synthesized and released by the pineal gland in the brain. Its primary roles are as a chronobiotic agent, regulating the body’s circadian rhythm or internal biological clock, and as a hypnotic agent, which at higher doses can induce sleepiness. Crucially, while the hypnotic effect is not universally experienced, the chronobiotic effect is present in all individuals. The natural increase in melatonin levels typically occurs one to three hours before bedtime, signaling the body’s readiness for sleep. This process is often referred to as the "dim light melatonin onset" (DLMO).
For children experiencing insomnia, particularly those with delayed sleep onset, melatonin is sometimes administered after their scheduled bedtime has passed, indicating that their bodies are not yet biologically prepared for sleep. This is a key reason why behavioral interventions like "bedtime fading," which aligns bedtime with the child’s natural sleep window, can be highly effective. Clinical doses of melatonin, ranging from 0.5 mg to 10 mg or even higher, often significantly exceed the physiological amounts secreted by the body. This distinction between natural physiological levels and therapeutic or supplement-induced doses is critical for understanding potential effects and risks.
Efficacy of Melatonin in Pediatric Sleep Disorders
The reported benefits of melatonin for children’s sleep often include a reduction in the time it takes to fall asleep and an increase in overall sleep duration. However, it is essential to acknowledge that the scientific literature on melatonin’s efficacy in children is still developing, with many studies involving small sample sizes and limited follow-up periods. A significant factor contributing to this is melatonin’s regulatory status in the United States, where it is classified as a dietary supplement rather than a pharmaceutical drug by the Food and Drug Administration (FDA). This classification means that large-scale, long-term clinical trials, typically funded by pharmaceutical companies for drug development, are less common for melatonin.
Despite these limitations, a general consensus suggests that melatonin can provide approximately 30 minutes of additional sleep per night, primarily by reducing sleep onset latency. While this can be a meaningful improvement for some children, it is not a panacea. The International Pediatric Sleep Association (IPSA) offers comprehensive reviews and dosing recommendations, including parent guides in multiple languages and literature reviews on melatonin use in both typically developing children and those with autism spectrum disorder (ASD).
Chronic Sleep Onset Insomnia in Typically Developing Children
Sleep onset insomnia, characterized by difficulties falling asleep, is a prevalent issue among children. When these difficulties occur at least three times a week for three months or more, leading to dissatisfaction with sleep or daytime impairments, it is classified as chronic insomnia. A 2023 meta-analysis by Edemann-Callesen, which aggregated data from 419 children, indicated an average increase of approximately 30 minutes in total sleep time, with about 18 minutes attributed to a reduction in sleep latency. Notably, this study found no significant improvement in daytime functioning and an increase in reported adverse events in the group receiving melatonin compared to a placebo.
The 2025 IPSA position paper on melatonin for typically developing children offers crucial recommendations for healthcare providers, emphasizing a cautious and evidence-based approach to its use.
Melatonin and Autism Spectrum Disorder (ASD)
Sleep disturbances are particularly common in children with Autism Spectrum Disorder (ASD), manifesting as prolonged sleep onset latency, reduced nighttime sleep, and difficulties with nighttime and early morning awakenings. Some research suggests that children with ASD may exhibit lower baseline levels of melatonin and reduced daily fluctuations in its secretion. Consequently, melatonin has been frequently employed to address these sleep challenges, often resulting in improved sleep onset and duration. Studies have explored both immediate-release and extended-release formulations, with dosing typically administered 30-60 minutes before bedtime.
A 2025 meta-analysis by Yang et al. reported that the most significant benefits of melatonin in children with ASD were observed in sleep efficiency and total sleep time, rather than sleep latency. The study also indicated that older children benefited more from melatonin, and the effectiveness could diminish over time. Higher doses appeared to be more impactful than lower doses.
A 2017 trial investigating a time-released melatonin preparation (PedPRM) at doses of 2-5 mg found that children in the study slept an average of 57.5 minutes longer than those in the control group. The primary benefit was attributed to a reduction in sleep onset latency, with treated children falling asleep approximately 39 minutes faster. While this medication, known as Slenyto in Europe, is not currently approved by the FDA for use in the USA, its findings contribute to the ongoing research.
The 2024 IPSA recommendations for melatonin use in children with ASD include specific guidelines for dosage and duration. A 2020 guideline from the American Academy of Neurology, co-authored by Dr. Ashura Buckley, recommends addressing behavioral management strategies first, followed by short-acting melatonin, and then extended-release formulations if necessary. These guidelines advocate for starting with low doses and gradually increasing them, always in conjunction with behavioral interventions. Resources like the Autism Speaks Sleep Toolkit and the book "Solving Sleep Problems in Children with Autism Spectrum Disorders" offer valuable support for families navigating these challenges.
Melatonin and Attention-Deficit/Hyperactivity Disorder (ADHD)
Sleep problems are frequently comorbid with Attention-Deficit/Hyperactivity Disorder (ADHD), and conversely, sleep disturbances can exacerbate attentional issues. Historical accounts, such as an early paper describing the "hyperkinetic behavior syndrome" (now referred to as ADHD), noted that parental desperation over nighttime sleep problems often overshadowed daytime challenges. It is estimated that up to 70% of children with ADHD experience sleep issues, including difficulty falling asleep, altered sleep architecture, and daytime sleepiness.
A 2024 review article by Cortese on managing sleep issues in ADHD highlighted two randomized controlled trials demonstrating positive effects. A systematic review by Larsson in 2024 indicated a 30-minute decrease in sleep latency and improved sleep efficiency, but found no evidence of improvement in quality of life or daytime ADHD symptoms. While a small trial suggested melatonin could help children with ADHD on stimulant medication, this finding was based on chart review and requires further validation.
Delayed Sleep Phase Syndrome (DSPS) and Melatonin
Delayed Sleep Phase Syndrome (DSPS) is a common disorder among adolescents, characterized by a significant shift in their natural sleep-wake cycle, making it difficult to fall asleep at conventional times and consequently impacting their academic and social commitments. Teens with DSPS often struggle to fall asleep until the early morning hours, sometimes as late as 4-5 AM. Melatonin plays a particularly prominent role in managing DSPS. Administering small doses several hours before the typical sleep onset, in conjunction with light exposure management, sleep hygiene practices, and gradual schedule adjustments (chronotherapy), can effectively shift sleep periods earlier. This is due to a marked delay in the DLMO, which melatonin can help advance. For children with DSPS, a recommended approach involves administering a dose 4-6 hours before their current sleep onset time, gradually advancing it every 4-5 days, using low-dose preparations. Among the various conditions discussed, DSPS demonstrates the clearest and most consistent benefit from melatonin intervention.
Melatonin in Children with Neurodevelopmental Delay and Blindness
Children with various forms of neurodevelopmental delay may experience significant insomnia, and melatonin can offer relief. However, in some cases, melatonin use has been associated with persistently elevated daytime melatonin levels, leading to daytime sleepiness. A 2023 review by Edemann-Callesen, examining melatonin use in a mixed group of conditions including neurodevelopmental disorders, found a modest increase in total sleep time (primarily due to reduced latency) but no significant improvement in subjective sleep quality or daytime functioning.
For children with blindness, the absence of light cues can disrupt their circadian rhythm, leading to sleep-wake cycle disturbances. While small trials in adults have shown some benefit, data on melatonin’s efficacy in visually impaired children remains limited.
Eczema and Melatonin
The discomfort associated with eczema, characterized by dry, itchy skin, can lead to sleep disturbances and non-restorative sleep in children. Some research suggests that children with eczema may have lower melatonin levels, and a recent trial indicated that melatonin supplementation could be beneficial.
Emerging Concerns and Regulatory Oversight
Despite its widespread use and perceived safety, several areas of concern warrant attention regarding melatonin. These include potential known and theoretical side effects, as well as issues related to product preparation and labeling.
Theoretical Side Effects: A primary theoretical concern is the potential for melatonin administration in children to lead to persistently elevated blood melatonin levels throughout the day. This could result in daytime sleepiness, though other long-term effects remain unclear. It is critical to reiterate that melatonin has not undergone the same rigorous testing as pharmaceutical drugs due to its classification as a dietary supplement by the FDA. Long-term safety studies have often relied on parental reports rather than objective biochemical testing. Dr. David Kennaway, a physician from Australia, has published editorials highlighting the inadequacy of long-term safety data for children, noting that melatonin is also used as a veterinary drug to alter the reproductive cycles of sheep and goats. This underscores the need for greater caution and further research.
Preparation and Labeling Issues: The regulatory oversight for dietary supplements, including melatonin, is substantially less stringent than for pharmaceuticals, impacting both safety and efficacy. Furthermore, the labeling of melatonin preparations can be frequently misleading. For instance, a liquid preparation labeled as "1 mg" may contain only 0.25 mg per dropperful, with the accurate dosage information often relegated to the package insert or website, which many consumers may not consult. This ambiguity can lead to accidental under- or overdosing.
While a 2020 study following 80 children on an extended-release melatonin formulation (PedPRM) for two years found no evidence of adverse effects on weight, height, body mass index, or sexual development, this remains one of the most robust long-term safety studies. The medical community desires more such comprehensive long-term investigations.
Navigating Melatonin Use: Guidance for Parents and Physicians
For parents whose children are already using melatonin, it is crucial to approach the situation with measured concern rather than panic. While concrete evidence of significant harm is limited, discussing the necessity of melatonin with a pediatrician is highly recommended, especially if its use was initiated without medical consultation. For children on long-term melatonin therapy who are sleeping well, a gradual dose reduction and assessment of continued need can be considered. The goal should be to transition towards using melatonin as needed rather than on a nightly basis.
Reinforcing robust sleep hygiene practices is paramount. This includes establishing a consistent and high-quality bedtime routine, limiting screen time for at least an hour before bed, and ensuring an appropriate sleep schedule. Current recommendations from IPSA suggest limiting melatonin use to 3-6 months and periodically attempting to discontinue it.
Ensuring safe storage and appropriate dosing of melatonin is essential to prevent accidental ingestion or overdose. Parents should be aware of potential interactions with other medications.
Informed Decision-Making: Timing, Dosage, and Preparation
When melatonin is deemed appropriate, careful consideration of its administration is vital. The timing of melatonin dosage significantly impacts its effects. A small dose administered a few hours before bedtime can be more effective than a larger dose given at bedtime, as it aligns better with the natural chronobiotic function of the hormone. Generally, administering melatonin 30-60 minutes before bedtime is considered optimal, although earlier administration may be beneficial in some cases.
The 2025 IPSA guidelines provide age-based dosing recommendations, emphasizing a gradual increase starting from 0.5 mg, with weekly increments of 0.5 mg until desired improvement or the maximum dose is reached. These guidelines aim to establish the safest and most effective dosage for each child.
Crucially, melatonin should never be viewed as a substitute for good sleep hygiene. Its use must be integrated with a high-quality bedtime routine, appropriate limitations on light exposure (especially from screens), and an appropriate sleep schedule. When possible, selecting USP Verified preparations can offer an added layer of assurance regarding product quality and manufacturing standards.
The Takeaway: A Balanced Perspective on Melatonin
The decision to medicate a child for sleep issues is often made after extensive deliberation and repeated attempts at behavioral interventions. The lack of FDA-approved insomnia medications for children, excluding chloral hydrate which is largely unavailable, leaves limited options. Melatonin is frequently utilized in pediatric practice and can be highly beneficial for many children and families. While acknowledging the concerns raised by some experts regarding long-term safety and regulatory oversight, the profound impact of poor sleep on children and families cannot be understated.
The primary objective in managing pediatric sleep disorders is to achieve restful sleep with minimal reliance on medication. For some children, particularly those with autism or developmental challenges, medication may be necessary for achieving adequate sleep. In such cases, melatonin can be a valuable option. However, it is imperative that its use is guided by thorough medical evaluation to rule out other underlying causes of insomnia, such as restless leg syndrome. The ultimate goal remains to help children achieve healthy sleep, and for many, melatonin, when used judiciously and in conjunction with sound sleep practices, can be a supportive tool in this endeavor.
